Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDev starts self-expanding stent trial

This article was originally published in Clinica

Executive Summary

IDev Technologies has enrolled the first patient in a trial of its self-expanding Supera stent. The 258-patient SUPERB study aims to demonstrate the safety and efficacy of the device in the treatment of obstructive arterial disease in the superficial femoral artery. The US FDA granted 510(k) clearance for Supera in August 2006 for the palliative treatment of biliary strictures caused by malignant neoplasms. Houston, Texas-based IDev also CE marked the stent for sale in Europe in May 2006 for biliary and peripheral vascular indications. Peripheral arterial disease of the lower extremities affects approximately 8-12 million people in the US, according to the American Heart Association.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel